Stay updated with breaking news from Test Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review Biologic License... | January 6, 2023
New drug application (NDA) for zilucoplan seeks approval for the treatment of generalized myasthenia gravis (gMG) in adult patients who are acetylcholine...
/PRNewswire/ -- UCB, a global biopharmaceutical company, announced today it is presenting results from across its portfolio in generalized myasthenia gravis...
UCB, a global biopharmaceutical company, today announced results from two Phase 3 studies evaluating its investigational treatments, zilucoplan, a self-administered, subcutaneous (SC) peptide inhibitor of complement component 5 (C5 inhibitor) and rozanolixizumab, an SC-infused monoclonal antibody targeting the ...
Press release content from PR Newswire. The AP news staff was not involved in its creation.